A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT03451851
- Locations
- π©πͺ
Universitatsklinikum Carl Gustav Carcus Dresden, Dresden, Germany
π©πͺUniversitatsklinikum Frankfurt, Frankfurt, Germany
π¨π¦Kirk Barber Reseach Inc., Calgary, Alberta, Canada
A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT03441529
- Locations
- π§πͺ
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 49
- Registration Number
- NCT03438461
- Locations
- πΊπΈ
PRAHS, Salt Lake City, Utah, United States
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 252
- Registration Number
- NCT03434041
- Locations
- πΊπΈ
The Medical Research Network, LLC, New York, New York, United States
π¨π³Beijing HuiLong Guan Hospital, Beijing, China
πΊπΈAtlanta Center for Medical Research, Atlanta, Georgia, United States
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 136
- Registration Number
- NCT03431350
- Locations
- π¨π¦
Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada
πΊπΈUrological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
πΊπΈThe Urology Center of Colorado, Denver, Colorado, United States
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-01-26
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 265
- Registration Number
- NCT03412565
- Locations
- πΊπΈ
Cancer Center of Central Connecticut - Southington, Southington, Connecticut, United States
πΊπΈMayo Clinic in Florida, Jacksonville, Florida, United States
πΊπΈAvera Medical Group - Oncology & Hematology, Sioux Falls, South Dakota, United States
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-55375515 Dose Level 1Drug: JNJ-55375515 Dose Level 2Drug: JNJ-55375515 Dose Level 3Drug: JNJ-55375515 Dose Level 4Drug: JNJ-55375515Drug: JNJ-55375515 Dose Level 5Drug: JNJ-55375515 Dose Level 6Drug: Placebo
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 42
- Registration Number
- NCT03405441
- Locations
- π³π±
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen, Netherlands
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Drug: TAR-200
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 35
- Registration Number
- NCT03404791
- Locations
- πΊπΈ
Mayo Clinic Arizona, Phoenix, Arizona, United States
πΊπΈUniversity of Rochester, Rochester, New York, United States
πͺπΈInst. Valenciano de Oncologia, Valencia, Spain
Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 320
- Registration Number
- NCT03399799
- Locations
- πͺπΈ
Hosp. Univ. Germans Trias I Pujol, Badalona, Spain
πͺπΈHosp Univ Fund Jimenez Diaz, Madrid, Spain
πͺπΈClinica Univ. de Navarra, Pamplona, Spain
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
- Conditions
- Urothelial Cancer
- Interventions
- Drug: ErdafitinibDrug: VinflunineDrug: PembrolizumabDevice: Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)Drug: Docetaxel
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 629
- Registration Number
- NCT03390504
- Locations
- π¨π¦
Saskatchewan Cancer Agency (SCA) - Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
πΊπΈUniversity of Miami Sylvester Cancer Center, Miami, Florida, United States
πΊπΈOncology Hematology Care, Cincinnati, Ohio, United States